Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Science

Volumn 359, Issue 6377, 2018, Pages 801-806

  Miao, Diana ^a,b   Margolis, Claire A ^a,b   Gao, Wenhua ^a   Voss, Martin H ^c,d   Li, Wei ^a   Martini, Dylan J ^a   Norton, Craig ^a   Bossé, Dominick ^a   Wankowicz, Stephanie M ^a,b   Cullen, Dana ^e   Horak, Christine ^e   Wind Rotolo, Megan ^e   Tracy, Adam ^b   Giannakis, Marios ^a,b   Hodi, Frank Stephen ^a   Drake, Charles G ^f   Ball, Mark W ^g   Allaf, Mohamad E ^g   Snyder, Alexandra ^c,j   Hellmann, Matthew D ^c,d   Ho, Thai ^h   Motzer, Robert J ^c,d   Signoretti, Sabina ^a   Kaelin, William G ^a,i   Choueiri, Toni K ^a   Van Allen, Eliezer M ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f Medical Center ^*  (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j ADAPTIVE BIOTECHNOLOGIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; IMMUNE CHECKPOINT INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; JANUS KINASE; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NONHISTONE PROTEIN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR;

CANCER; CELL; ENZYME; ENZYME ACTIVITY; GENE EXPRESSION; GENOMICS; INHIBITOR; SUCROSE; TUMOR;

ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 3P; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG RESPONSE; DRUG TARGETING; GENE DELETION; GENE EXPRESSION; GENE LOCATION; GENE LOSS; GENETIC CORRELATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNE CHECKPOINT BLOCKADE THERAPY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; INDEL MUTATION; KIDNEY METASTASIS; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MONOTHERAPY; MUTATIONAL ANALYSIS; NONSENSE MUTATION; ONCOGENE; ONCOGENE CCL21; ONCOGENE IL10; ONCOGENE IL12; ONCOGENE IL6; ONCOGENE JAK; ONCOGENE PBRM1; ONCOGENE STAT3; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RENAL CELL CARCINOMA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VALIDATION STUDY; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; EXOME; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; IMMUNOTHERAPY; KIDNEY TUMOR; MUTATION; PROCEDURES;

B7-H1 ANTIGEN; CARCINOMA, RENAL CELL; CHROMOSOMAL PROTEINS, NON-HISTONE; COHORT STUDIES; CTLA-4 ANTIGEN; EXOME; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSCRIPTION FACTORS;

EID: 85040072272     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aan5951     Document Type: Article

References (38)

1. R. J. Motzer et al., N. Engl. J. Med. 373, 1803–1813 (2015).
2. A. Snyder et al., N. Engl. J. Med. 371, 2189–2199 (2014).
3. N. A. Rizvi et al., Science 348, 124–128 (2015).
4. D. T. Le et al., N. Engl. J. Med. 372, 2509–2520 (2015).
5. E. M. Van Allen et al., Science 350, 207–211 (2015).
6. C. J. Creighton et al., Cancer Genome Atlas Research Network, Nature 499, 43–49 (2013).
7. G. de Velasco et al., Cancer Immunol. Res. 4, 820–822 (2016).
8. M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, N. Hacohen, Cell 160, 48–61 (2015).
9. Y. Şenbabaoğlu et al., Genome Biol. 17, 231 (2016).
10. T. K. Choueiri et al., Clin. Cancer Res. 22, 5461–5471 (2016).
11. Materials and methods are available as supplementary materials.
12. J. D. Wolchok et al., Clin. Cancer Res. 15, 7412–7420 (2009).
13. E. A. Eisenhauer et al., Eur. J. Cancer 45, 228–247 (2009).
14. O. N. Gofrit et al., Springerplus 4, 580 (2015).
15. M. S. Lawrence et al., Nature 499, 214–218 (2013).
16. S. L. Carter et al., Nat. Biotechnol. 30, 413–421 (2012).
17. I. Varela et al., Nature 469, 539–542 (2011).
18. M. Gerlinger et al., Nat. Genet. 46, 225–233 (2014).
19. A. M. Nargund et al., Cell Reports 18, 2893–2906 (2017).
20. W. Gao, W. Li, T. Xiao, X. S. Liu, W. G. Kaelin Jr., Proc. Natl. Acad. Sci. U.S.A. 114, 1027–1032 (2017).
21. A. Subramanian et al., Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550 (2005).
22. P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Cell 168, 707–723 (2017).
23. Y. Sato et al., Nat. Genet. 45, 860–867 (2013).
24. A. G. Ramsay, Br. J. Haematol. 162, 313–325 (2013).
25. J. E. Rosenberg et al., Lancet 387, 1909–1920 (2016).
26. S. L. Topalian et al., N. Engl. J. Med. 366, 2443–2454 (2012).
27. C. Kadoch et al., Nat. Genet. 45, 592–601 (2013).
28. D. Pan et al., Science 359, 770–775 (2018).
29. B. Beuselinck et al., Clin. Cancer Res. 21, 1329–1339 (2015).
30. A. P. Fay et al., J. Natl. Compr. Canc. Netw. 14, 820–824 (2016).
31. A. A. Hakimi et al., Clin. Cancer Res. 19, 3259–3267 (2013).
32. J. J. Hsieh et al., Eur. Urol. 71, 405–414 (2017).
33. P. Kapur et al., Lancet Oncol. 14, 159–167 (2013).
34. D. J. Kwiatkowski et al., Clin. Cancer Res. 22, 2445–2452 (2016).
35. S. J. Nam, C. Lee, J. H. Park, K. C. Moon, Urol. Oncol. 33, 340.e9–340.e16 (2015).
36. R. Pawłowski et al., Int. J. Cancer 132, E11–E17 (2013).
37. M. Uhlen et al., Science 357, eaan2507 (2017).
38. M. I. Carlo et al., Kidney Cancer 1, 49–56 (2017).